Table 1.

Patients' baseline characteristics and association/correlation of PD-1 DNA methylation with clinicopathological parameters—TCGA cohort.

Variable	All patients	[%]	Mean PD-1 methylation	p-value
Patient number	498	100	55.5 [54.4–56.6]
Patient with follow-up	430	86.3
Mean follow-up [Mo]	22 [20–24]
Median follow-up [Mo]	16
Range follow-up [Mo]	1–115
Age [y]
Mean	61.0 [60.4–61.6]
Median	61.0
n ≤ Median	251	50.4	55.2 [53.7–56.8]
n > Median	247	49.6	55.8 [54.2–57.3]	0.58*
Pathological tumor category
pT1/2	188	37.8	54.3 [52.5–56.1]
pT3/4	303	60.8	56.3 [54.9–57.7]	0.10*
Unknown	7	1.4
Preoperative PSA [ng/mL]
Range	0.7–107.0
Mean	11.0 [9.9–12.1]
Median	7.5
≤Median	252	50.6	54.1 [52.5–55.6]
>Median	243	48.8	56.8 [55.3–58.4]	0.025*
Unknown	3	0.6
ISUP Gleason grading group
1 (<7 )	45	9.0	53.9 [50.3–57.5]
2 (3+4)	147	29.5	54.0 [52.0–55.9]
3 (4+3)	101	20.3	57.1 [54.9–59.3]
4 (8)	64	12.9	55.3 [51.5–59.1]
5 (9−10)	141	28.3	56.5 [54.4–58.6]	0.30ε
Nodal category
pN0	346	69.5	55.5 [54.1–56.7]	0.45*
pN1	79	15.9	56.2 [53.2–59.1]
Unknown	73	14.7
Surgical margin
R0	316	63.5	55.3 [53.9–56.7]
R1	147	29.5	55.7 [53.8–57.7]	0.81*
unknown	35	7.0
ERG-translocation1
ERG+	152	30.5	57.9 [56.0–59.7]	0.006*
ERG−	181	36.3	54.6 [52.9–56.4]
Unknown	165	33.1
Androgen receptor (AR) score1
AR+	166	33.3	57.6 [55.9–59.3]
AR-	167	33.5	54.7 [52.8–56.5]	0.021*
Unknown	165	33.1

^*Mann–Whitney U test

^εKruskal–Wallis test

¹adopted from the Cancer Genome Atlas Research Network (2015)¹⁰.

Significant features are printed in bold.